◆ TICKERBASEVisão interativa →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

InícioTodas as ações › MANKIND · English version

Mankind Pharma Limited (MANKIND)

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

Healthcare · Wall Street (EUA) · Última atualização: 2026-09-20

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases.

Números-chave

Ver gráficos interativos e demonstrações completas →

Demonstração de resultados anual

Demonstração de resultados2026-03-312025-03-312024-03-312023-03-31
Receita total₹142.8B₹122.1B₹102.6B₹87.5B
Lucro bruto₹101.3B₹86.4B₹70.0B₹57.9B
Resultado Operacional (EBIT)₹28.4B₹25.2B₹22.4B₹16.4B
Resultado líquido₹19.1B₹19.9B₹19.1B₹12.8B

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de MANKIND. /companies/us/MANKIND

Empresas semelhantes

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.